Canada: While Americans Laud "Low" Canadian Drug Prices, Canadian Innovative Pharma Waits To See If The Pricing Axe Will Fall On "Excessive" Canadian Drug Prices

Whether a Canadian drug price is a bargain or excessive may depend on which side of the border you view it from. In the U.S. there has been a lot of discussion about how inexpensive Canadian drug prices are compared to the U.S. The U.S. federal government has recently gone so far as to propose a federal framework that may permit exportation of certain drugs from Canada into the US. 

However, in Canada, the view of the federal drug price regulator, the Patented Medicines Price Review Board (PMPRB), is that Canadian patented drug prices are generally too high. The same regulator also believes that generic drug prices are too high, but generic drugs are not the subject of this article1

The PMPRB is an independent, quasi-judicial body with the mandate of ensuring that prices charged by patentees for patented medicines sold in Canada are not excessive. It also reports on pharmaceutical price trends of medicines, and on R&D spending by pharmaceutical patentees. The Regulations have not been overhauled in the past 20 years.

In May 2017, Health Canada (Canada’s equivalent of the U.S. FDA or the European Medicines Agency) published a regulatory proposal called “Protecting Canada from Excessive Drug Prices” containing a series of amendments to the Regulations2. The bottom line of these amendments was that they were expected to substantially lower patented drug prices. After two years of intense opposition from the Canadian pharmaceutical industry and certain patient organizations, no amendments have come into effect. The government has provided recent assurances that the much anticipated revised draft amendments are still on track for publication soon.

Proposed amendments to the Regulations

In May 2017, the government outlined its comprehensive plan revising the patented drug price review system in Canada. Its stated goal was to enable the PMPRB to better protect Canadians from paying excessive prices for patented drugs3. Proposed amendments to the Regulations were pre-published in December 20174. The PMPRB also released a Guidelines Scoping paper intended to be read in conjunction with the proposed amendments5. The proposed amendments included new price regulation factors to be considered. It also updated the schedule of price comparator countries, and provided new reporting requirements. It also contained a cost-benefit statement that estimated that the proposed amendments would produce a net benefit to Canadians of $12.6 billion over 10 years due to reduced prices for patented medicines.

Backlash and stakeholder consultations

The government’s cost savings was quickly recognized as innovative pharma’s profit loss. The PMPRB’s faced swift backlash from the pharmaceutical industry and certain patient groups6. Chief among their criticisms were that the proposed amendments and price reductions would reduce the availability of new therapies for Canadian patients. There were also warnings that price reductions might result in reduced R&D in Canada and employment losses.

In response to this uproar, the PMPRB decided to engage in further consultations. It established a steering committee with the mandate to assist the PMPRB in “synthesizing stakeholder views on key technical and operational modalities of the PMPRB’s new draft Guidelines.” Starting in June 2018, PMPRB began holding targeted consultations with its stakeholders on key aspects of a new Guidelines framework which would implement the proposed amendments. There were two main camps in these consultations. In the first were industry representatives such as Innovative Medicines Canada, representing more than 45 pharmaceutical companies, as well as patient organizations. In the second, the payers, who were representatives from provincial agencies and the private insurance industry.

The PMPRB then created a Working Group of experts7 that met in July 2018. The Working Group had the mandate to ‘inform the Steering Committee on certain issues that the Steering Committee believed would benefit from the review of experts in health technology assessment and other economic and scientific matters’. The Working Group was intended to include leading experts in pharmacoeconomics and clinical evaluation of pharmaceuticals.

The January 2019 implementation date for the Regulations was abandoned. The consultation process was planned to conclude in the fall of 2018, but as reported in the October 2018 PMPRB newsletter: “progress on the issues under discussion has been slower than anticipated, owing to the complexity of the subject matter and conflicting views of participants on the merits of the underlying policy”8.

Minister of Health: “Stay tuned”

The Working Group’s report was completed in March 2019 and is available on the PMPRB’s website9. The Steering Committee held what was expected to be its final meeting on May 13, 2019, to discuss a draft report of its own deliberations10. The PMPRB newsletter indicated that once the Steering Committee finalized its report and the revised Regulations had been published, the PMPRB would release new draft Guidelines for public consultation.

There is an expectation that the revised regulations will be released in the near future based on recent comments by Federal Minister of Health Ginette Petitpas Taylor. On May 28, 2019, at a meeting of the House of Commons Standing Committee on Health (HESA), the Minister stated that “…we’re still in the process of modernizing the [PMPRB]. That work is well under way, and there will be some announcements to be made” and that “there’s going to be an announcement in the very near future. Stay tuned.”11 It is not clear if the coming Federal election in October 2019 will affect that timetable. We will provide an update once the revised Regulations are published.

Footnotes

1 The PMPRB stated in its report, “Generics360 – Generic Drugs in Canada, 2016” that, “the implementation of pricing policies in Canada has markedly reduced the price of generic drugs, reining in the growth in sales, international generic prices are still significantly lower.”

2 Health Canada, Protecting Canadians from Excessive Drug Prices: Consulting on Proposed Amendments to the Patented Medicines Regulations (Consultation) (Ottawa: Health Canada, 2017).

3 Ibid.

4 Regulations Amending the Patented Medicines Regulations, (2017) C Gaz I, 4497.

5 Canada, Patented Medicine Price Review Board, PMPRB Guidelines Scoping Paper—High Level Overview of Potential New Framework (Ottawa: PMPRB, 2018).

6 Kelly Crowe, “Canada has found the key to lowering drug prices, but it won’t be used any time soon”, CBC News (26 November 2018), online: <https://www.cbc.ca/news/health/canada-drug-price-patented-medicine-pharmaceutical-industry-pmprb-1.4919200>.

7 Working Group to Inform the Patented Medicine Prices Review Board (PMPRB) Steering Committee on Modernization of Price Review Process Guidelines.

8 Canada, Patented Medicine Price Review Board, PMPRB NEWSletter, vol 22 issue 4 (Ottawa: PMPRB, 2018), online: < http://www.pmprb-cepmb.gc.ca/view.asp?ccid=1412&lang=en#a1>.

9 Canada, Patented Medicine Price Review Board, Working Group to Inform the Patented Medicine Prices Review Board (PMPRB) Steering Committee on Modernization of Price Review Process Guidelines: Final Report – March 2019 (Ottawa: PMPRB, 2018), online: <http://www.pmprb-cepmb.gc.ca/view.asp?ccid=1449&lang=en>.

10 Canada, Patented Medicine Price Review Board, PMPRB NEWSletter, vol 23 issue 1 (Ottawa: PMPRB, 2019), online: <http://www.pmprb-cepmb.gc.ca/view.asp?ccid=1452>.

11 House of Commons, Standing Committee on Health, Evidence, 42-1, No 148 (May 2019), online: <https://www.ourcommons.ca/DocumentViewer/en/42-1/HESA/meeting-148/evidence>.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions